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Introduction: For the majority of patients with non–small-cell lung 
cancer (NSCLC), response to epidermal growth factor receptor tyro-
sine kinase inhibitors (EGFR-TKIs) is suboptimal. In models of 
acquired resistance to EGFR-TKI, activation of Akt phosphorylation 
is frequently observed. Because Akt activation results in downstream 
initiation of cap-dependent protein translation, we hypothesized that 
a strategy of targeting cap-dependent translation in combination with 
erlotinib might enhance therapy.
Methods: NSCLC cells that are wild type for EGFR were assayed for sen-
sitivity to erlotinib. Serum-starved NSCLC cells were assayed for EGFR 
signaling and downstream pathway activation by immunoblot after stimu-
lation with epidermal growth factor. EGFR signaling and signaling medi-
ators of cap-dependent translation were assayed by immunoblot under 
serum-replete conditions 24 hours after treatment with erlotinib. Finally, 
combination treatment with erlotinib and two different cap-dependent 
translation inhibitors were done to assess the effect on cell viability.
Results: EGFR signaling is coupled to activation of cap-dependent 
translation in EGFR wild-type cells. Erlotinib inhibits EGFR phos-
phorylation in EGFR-TKI resistant cells, however, results in activation 
of downstream signaling molecules including Akt and extracellular 
regulated kinase, ERK 1/2, resulting in maintenance of eukaryotic 
initiation factor 4F (eIF4F) activation. eIF4F cap-complex formation 
is maintained in erlotinib-resistant cells, but not in erlotinib-sensitive 
cells. Finally, using an antisense oligonucleotide against eukaryotic 
translation initiation factor 4E and a small-molecule inhibitor to dis-
rupt eIF4F formation, we show that cap-dependent translation inhibi-
tion can enhance sensitivity to erlotinib.
Conclusion: The results of these studies support further clinical 
development of translation inhibitors for treatment of NSCLC in 
combination with erlotinib.
Key Words: Epidermal growth factor receptor, Erlotinib, Non–
small-cell lung cancer, Eukaryotic translation initiation factor 4E, 
Cap-dependent translation.
(J Thorac Oncol. 2013;8: 1142-1147)
Non–small-cell lung cancer (NSCLC) remains the lead-ing cause of cancer-related death worldwide.1 The out-
comes with standard chemotherapy have reached a plateau in 
terms of efficacy, and novel targeted therapies have made their 
way into the standard treatment of NSCLC. The epidermal 
growth factor receptor (EGFR) has emerged as a major target 
for NSCLC therapy with the seminal BR.21 trial demonstrat-
ing a modest but significant improvement in overall survival 
in patients treated with erlotinib, an EGFR tyrosine kinase 
inhibitor (TKI), in the second line.2 Although every subset in 
that randomized trial showed some benefit to erlotinib, it is 
now clear that the small fraction of patients harboring an acti-
vating mutation in the EGFR tyrosine kinase domain get the 
most benefit, with objective response rates of about 60%.3–5 
Despite prevalent overexpression of EGFR, the response rates 
in EGFR wild-type (WT) patients is less than 10% with stable 
disease in about 50%. Therefore, although EGFR-directed 
therapy remains a viable option for patients with EGFR-WT 
tumors, the results are suboptimal.
Experimental models of EGFR-TKI acquired resistance 
demonstrate that activation of downstream pathways either 
through Kirsten rous sarcoma mutation or amplification of 
redundant pathways such as insulin-like growth factor receptor 
(IGFR) or mesenchymal-epithelial transition (c-Met) mediates 
such resistance.6–8 On the basis of these studies, two clinical 
trials have been completed to test the strategy of combination 
treatment of erlotinib in combination with c-Met and IGFR 
inhibitors.9 Still, other data show that there are potentially 
numerous other pathways that might result in resistance to 
erlotinib such as Her2 and Her3, among others.10 Therefore, the 
best strategy for combination therapy with EGFR-TKI is not 
entirely straightforward and the correct biomarker to choose 
which combination to consider is not entirely clear at this time.
We and others have demonstrated that the 5′-mRNA 
cap-dependent protein translational machinery is vital to lung 
tumorigenesis and progression.11–14 However, this autonomous 
translational activity is not associated with any known muta-
tions in the translational apparatus. Rather, the constitutive 
activity of the translational machinery seems to be mediated 
by active upstream signaling pathways that converge upon 
the eukaryotic initiation factor 4F (eIF4F) trimolecular com-
plex.15–17 Therefore, we hypothesize that eIF4F serves as a 
major regulatory node downstream of EGFR as well as several 
other alternate signaling pathways, and maintained activation 
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of cap-dependent protein translation because of redundant 
signaling may result in resistance to EGFR-TKI. This article 
describes experiments that show that most EGFR-WT NSCLC 
cells are primarily resistant to erlotinib treatment. Moreover, 
erlotinib treatment results in activation of Akt and maintenance 
of activated eIF4F complex formation. Finally, combination 
therapy with two different inhibitors of cap-dependent transla-
tion improved the efficacy of erlotinib against NSCLC cells in 
vitro. The result of this work supports further clinical develop-
ment of translation inhibitors in combination with erlotinib.
MATERIALS AND METHODS
Cell Lines and Reagents
Cells were obtained from the American Type Culture 
Collection (ATCC) or from the laboratory of Frederick Kaye 
(National Cancer Institute, Bethesda, MD). H2009, H522, 
H460, H520, H2030 were grown in Roswell Park Memorial 
Institute (RPMI) 1640 medium (Gibco, Invitrogen) with 10% 
calf serum (R10). H838 and H2122 were grown in R10 and 
L-glutamine, HEPES, glucose, and sodium bicarbonate supple-
ments. Erlotinib was obtained from LC laboratories (Woburn, 
MA). LY2275796 (antisense oligonucleotide to eIF4E or anti-
sense oligonucleotide to eIF4E) and mismatch antisense oligo-
nucleotide (MM-ASO) were obtained from Jeremy Graff (Eli 
Lilly and Company, Indianapolis, IN). 4EGI-1 was purchased 
from Chembridge Corporation (San Diego, CA).18
Cytotoxicity Assays
Cytotoxicity of erlotinib on NSCLC was performed by 
CCK-8 kit (Dojindo Molecular Technologies, Inc.) as previ-
ously described.19 Briefly, 2000 to 5000 cells were seeded onto 
96-well plates and allowed to adhere overnight. The follow-
ing day, medium containing various concentrations of erlo-
tinib were added to appropriate wells. After 72 hours, 10 μl 
of CCK-8 reagent were added to the wells and incubated for 4 
hours at 37°C. The color change was read on a 96-well plate 
reader at 405 nm of light. Experiments were performed in qua-
druplicate with untreated controls and additional wells were 
measured without cells as a background control.
Epidermal Growth Factor Stimulation
Cells were seeded onto 10-cm plates at 1.5 to 2.5 × 106 
cells and allowed to adhere overnight. The following night, cells 
were washed twice with phosphate-buffered saline and serum-
starved in RPMI overnight. The following morning, cells were 
stimulated with 100 ng/ml EGF with and without 1 μM erlo-
tinib. Cell extracts were prepared at 20, 60, and 150 minutes 
poststimulation. Cells were washed once with ice-cold 1X 
phosphate-buffered saline. 1X cell lysis buffer (Cell Signaling, 
Danvers, MA) containing phenylmethanesulfonylfluoride 
(PMSF) 1 mM was added directly to the plate followed by 
scraping of the cells, and the resulting lysate was immediately 
placed on ice. Cells were centrifuged to pellet nuclear material 
and cell debris and supernatants were stored at −80°C until use.
Immunoblots
Twenty-five to 100 μg of protein were subjected to 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and immunoblot as previously described.20 
Antibodies to p-EGFRTyr1068 (no. 2236), EGFR (no. 2646), 
p-IGFRTyr1135/1136 (no. 3024), p-c-MetTyr1003 (no. 3135), c-MET 
(no. 3127), p-JNKThr183/Tyr185 (no. 9251), JNK (no. 9252), 
p-AktSer473 (no. 9271), Akt (no. 9272), p-ERK1/2Thr202/Tyr204 (no. 
9101), ERK1/2 (no. 9102), 4E-BP1 (no. 9452), p-eIF4E (no. 
9741), and eIF4E (no. 9742) were obtained from Cell Signaling 
and used at 1:1000 dilution in Tris-buffered saline with 
Tween-20 (TBS-T) unless otherwise mentioned. Anti IGFR-β 
(sc-713) was obtained from Santa Cruz Biotechnology, Inc. 
Anti-eIF4G antibody (1:5000 dilution) was kindly provided 
by Nahum Sonenberg. βeta-actin (Cat.no. A1978; Sigma, St. 
Louis, MO) was used as a loading control (1:10000 dilution). 
Briefly, cells were plated onto 10-cm culture plates overnight 
in R10. The following day, cells were treated with erlotinib 2 
μM or 5 μM or equal volumes of drug vehicle (dimethyl sulf-
oxide ) as control. Twenty-four hours later, cells were lysed 
and stored at −80°C until used. Protein concentrations were 
determined using Bradford assay and then loaded onto 8% to 
15% SDS-PAGE gels, transferred to polyvinylidene fluoride 
(PVDF) (GE Healthcare, Piscataway, NJ), and assayed with 
abovementioned antibodies to determine protein expression.
Cap-Affinity Assay
Binding of eIF4E and binding partners eIF4G and 
4E-BP1 was determined using 7m-GTP sepharose beads (GE 
Healthcare) as previously described.16 Briefly, 300 μg of lysates 
were added to 50 μl of beads and rotated for 3 hours at 4°C. 
Beads were washed thrice with cell lysis buffer and binding pro-
teins were eluted using 5x-Laemmli’s buffer and boiled at 95°C 
for 5 minutes. These samples were then run on SDS-PAGE gels 
and subjected to immunoblot for eIF4E, eIF4G, and 4E-BP1.
RESULTS
A panel of NSCLC cell lines, all of which are EGFR-WT, 
were treated with various doses of erlotinib in vitro (Fig. 1). 
The majority of NSCLC cells were found to be resistant to 
erlotinib with IC
50
 that was greater than 5 μM. Only H2122 
was modestly sensitive with an IC
50
 of approximately 1 μM. 
These results are consistent with previously published data.21 
Next, the effect of EGF stimulation on downstream signaling 
pathways leading to cap-dependent translation was examined. 
Cells were serum-starved before EGF stimulation to take away 
any potential effect of other growth factors in the serum-replete 
medium. EGF stimulation led to activation of EGFR, which 
was inhibited if cells were pretreated with erlotinib (Fig. 2). 
Downstream phosphorylation of Akt and 4-EBP1 was observed 
after EGF stimulation of serum-starved cells. Erlotinib pretreat-
ment prevented Akt phosphorylation and subsequent hyper-
phosphorylation of 4E-BP1 in each of the cell lines after 20 
minutes of EGF stimulation. Erlotinib pretreatment also inhib-
ited ERK1/2 phosphorylation in all but H2009 cells. These data 
show that EGFR stimulation results in hyperphosphorylation of 
4E-BP1 and that EGFR-TKI treatment can inhibit downstream 
signaling regulating 4E-BP1 under serum-starved conditions. 
Furthermore, under these conditions, there was little difference 
in the signaling characteristics mediated by EGF stimulation 
between EGFR-sensitive and -resistant cells.
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Because we hypothesized that eIF4F activation upon 
EGFR-TKI administration would be sustained by alternate 
signaling pathways, we examined the signaling properties of 
erlotinib-resistant (H460, H520, H2009, and H522) compared 
with erlotinib-sensitive (H2122) cells after erlotinib treatment 
under serum-replete conditions (Fig. 3). For both erlotinib-sen-
sitive and -resistant cell lines, erlotinib administration resulted 
in inhibition of phosphorylated EGFR, suggesting that the 
drug was able to inhibit its target. However, in three of four 
erlotinib-resistant cell lines, phosphorylation of either IGFR 
or c-MET was observed 24 hours after treatment. In all of the 
resistant cell lines, Akt phosphorylation was enhanced or main-
tained 24 hours after erlotinib administration compared with 
vehicle control treated cells. Of the resistant cell lines, all but 
H522 showed enhanced or maintained 4E-BP1 phosphoryla-
tion despite erlotinib treatment. H460 demonstrated activation 
of Akt and ERK1/2 after erlotinib treatment despite inhibition 
of IGFR and c-Met phosphorylation, suggesting that another 
kinase pathway may play a role in maintaining activation of 
these pathways. In contrast, H2122 cells showed no increase in 
phosphorylated c-Met or IGFR in response to erlotinib treat-
ment. Furthermore, downstream Akt and 4E-BP1 phosphor-
ylation were markedly inhibited after erlotinib treatment in 
H2122 cells. For three of the four resistant cell lines, ERK and 
c-jun N-terminal kinase phosphorylation was also enhanced 
after erlotinib treatment, but not for H2122. In both resistant 
and sensitive cells, phosphorylation of eIF4E was diminished 
after erlotinib treatment. Although several reports indicate the 
FIGURE 1.  Non–small-cell lung 
cancer cells that are wild type for 
epidermal growth factor receptor were 
treated with increasing concentrations 
of erlotinib in a 96-well format. Data 
are expressed as a percent of viable 
cells compared with untreated cells 
after 72 hours of erlotinib exposure. 
Cells were treated in triplicate. H2122 
(black diamond) cells are the only cells 
that are sensitive to erlotinib. Error bars 
indicate standard deviation. *Indicates 
statistical significance at p < 0.05.
FIGURE 2.  Immunoblots of serum-starved non–small-cell lung cancers that were then stimulated with exogenous EGF. Lysates 
were made at indicated time points (minutes) and assessed for EGFR signaling and downstream pathway activation. Lane 2 
(indicated with an arrow) were lysates prepared from cells pretreated with erlotinib 2 μM and then EGF stimulated for 20 minutes. 
Phosphorylation of 4E-BP1 is indicated by an upward shift of the bands as the hyperphosphorylated forms migrate slower on the 
gel. The hyperphosphorylated forms are β, and γ, whereas hypophosphorylated are α. βeta-actin is used as a loading control. Sfm, 
serum-free medium; EGFR, epidermal growth factor receptor; ERK1/2, extracellular regulated kinase; 4E-BP1, eIF4E binding protein.
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phosphorylation of eIF4E contributes to enhanced eIF4F activ-
ity, there are conflicting data regarding the influence of eIF4E 
phosphorylation.20,22,23 These results indicate that in resistant 
cell lines, erlotinib treatment results in the activation of numer-
ous signaling pathways that maintain Akt phosphorylation and 
downstream formation of the eIF4F complex.
These cells were further analyzed by the 5′-cap affin-
ity assay using 7m-GTP sepharose beads to assay for binding 
of eIF4E to the cap and binding partners associated with it 
(Fig. 4A). In H2122 (erlotinib-sensitive) cells, erlotinib treat-
ment resulted in inactivation of the eIF4F complex as seen by 
dissociation of eIF4G from eIF4E. However, in H2009 cells, 
erlotinib treatment did not impact eIF4F complex formation. 
Thus, erlotinib sensitivity correlates with the ability to inhibit 
eIF4F activity. Therefore, we next analyzed the ability of spe-
cific translation inhibitors to restore sensitivity to erlotinib 
therapy. For these experiments, erlotinib-resistant cells were 
used. Two different translational inhibitors were used for these 
experiments. Antisense oligonucleotide to eIF4E (LY2275796 
or 4EASO) and 4EGI-1 were used either alone or in combi-
nation with erlotinib. Each of these drugs has been shown to 
inhibit eIF4F formation in vitro against NSCLC cells.18,24 The 
combination of 4EASO and erlotinib was additive for H2009 
and significantly enhanced the cytotoxicity compared with 
erlotinib alone (Fig. 4B). 4EGI-1 treatment, likewise, resulted 
in additive benefit in combination with erlotinib for H2009 
cells. For H460 and A549 cells, the combination was greater 
than additive implying potential synergy with the combination 
(p < 0.01 compared with either drug alone).
DISCUSSION
Taken together these data show that erlotinib sensitivity 
or resistance may be influenced by the ability to inhibit eIF4F 
formation and that primary resistance could be related to sus-
tained eIF4F activation in EGFR-WT NSCLC cells. These 
findings lend more credence to the observation of numerous 
other investigators that mRNA translation is a major regula-
tory checkpoint in cancer cells, which is a legitimate target 
for cancer therapy.25,26 Furthermore, in complex tumors with 
redundant signaling pathways, cap-dependent translation is an 
important downstream effector of these signaling pathways 
affecting cell survival and proliferation. Although numerous 
clinical trials are investigating the utility of combined EGFR 
and IGFR or combination EGFR/c-Met inhibition, the attenu-
ation of cap-dependent translation may be a more fruitful 
approach as it lays downstream of both of these important sig-
naling pathways and likely also is downstream of other kinase 
pathways that might mediate resistance such as Kirsten rous 
sarcoma, Src, Her3, and JNK.27–30
The combination of erlotinib with inhibition of cap-
dependent translation may also be useful in preventing the 
development of resistance to EGFR-TKI in EGFR mutated 
cells. Recent data indicate acquired resistance to EGFR-TKI 
may result in overexpression of eIF4E, and erlotinib-resistant 
EGFR mutant cells can become resensitized to EGFR-TKI 
treatment on inhibition of cap-dependent translation.31
Although the abovementioned results show a correla-
tion between erlotinib resistance and maintenance of cap-
dependent translation, other mechanisms may play a role as 
well. As was seen in the data mentioned above, several sig-
naling pathways are activated on erlotinib treatment and have 
pleiotropic effects on other pathways independent of transla-
tion. For example, Akt phosphorylation can have antiapoptotic 
effects by regulating p53 and effects on cell-cycle regulation 
in addition to translation control.32,33
Several inhibitors of cap-dependent translation are in 
early clinical development.34,35 Small-molecule inhibitors 
such as 4EGI-1 have suffered from a lack of clinical potency. 
LY2275796 has recently completed a phase I clinical trial in 
patients with solid tumors.36 The treatment was safe and well 
FIGURE 3.  Immunoblots of non–small-cell 
lung cancers that were treated with erlotinib 
under serum-replete conditions. Lysates 
were made 24 hours later and assessed for 
activation of downstream and parallel signal-
ing. βeta-actin is used as a loading control. 
Dimethyl sulfoxide (vehicle). In erlotinib-
sensitive cell lines, erlotinib treatment results 
in inhibition of downstream phosphoryla-
tion in Akt and 4E-BP1. In resistant cells, 
erlotinib results in activation of Akt and 
maintenance of 4E-BP1 phosphorylation. 
p-EGFR, phosphorylated epidermal growth 
factor receptor; p-IGFR, phosphorylated 
insulin-like growth factor receptor; p-JNK, 
phosphorylated jun N-terminal kinase; 
p-eIF4E, phosporylated eukaryotic translation 
initiation factor 4E; p-c-Met, phosphorylated 
mesenchymal-epithelial transition; 4E-BP1, 
eIF4E binding protein; p-ERK, phosphory-
lated extracellular regulated kinase.
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tolerated. There were no dose-limiting toxicities among the 
30 patients enrolled in the study, and only two patients had 
grade 3 fatigue. Despite posttreatment biopsies showing inhi-
bition of eIF4E expression in the tumor, there were no objec-
tive responders, and stable disease was the best response. The 
authors concluded that future trials of LY2275796 be con-
ducted in combination with other therapeutics. In preclinical 
studies, the combination of LY2275796 with chemotherapy 
results in enhanced cytotoxicity in NSCLC and mesothelioma 
(data to be published separately). Because of the excellent 
safety profile of LY2275796, the combination of translation 
inhibition in combination with EGFR-TKI might be a promis-
ing approach to treating EGFR-WT NSCLC.
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